首页> 中文期刊> 《中国实用医药》 >淋巴细胞免疫治疗复发性流产100例临床研究

淋巴细胞免疫治疗复发性流产100例临床研究

         

摘要

Objective To research the clinical effect of lymphocyte immunotherapy for recurrent spontaneous abortion patients.Methods A total of 100 recurrent spontaneous abortion patients were divided by their willing choice of treatment methods into immunotherapy group and tocolysis therapy group. The immunotherapy group (57 cases) received lymphocyte injection immunotherapy, and the tocolysis therapy group (43 cases) received progesterone injection. Pregnancy outcome, curative effective rate, and adverse reactions were compared between the two groups.Results The immunotherapy group had the treatment success rate as 82.56%, which was obviously higher than 20.93% of the tocolysis therapy group, and their difference had statistical significance (P<0.05). Incidence of adverse reactions in the tocolysis therapy group was 2%, and that in the immunotherapy group was 4%. Their difference had no statistical significance (P>0.05).Conclusion Lymphocyte immunotherapy has high effective rate and few adverse reactions in treating recurrent spontaneous abortion, and it is a safe and effective treatment method.%目的:研究淋巴细胞免疫治疗复发性流产患者的临床效果。方法100例复发性流产患者,按照患者意愿所选择的治疗方式将其分为免疫治疗组和安胎治疗组,免疫治疗组(57例)注射淋巴细胞免疫治疗,安胎治疗组(43例)采用注射黄体酮治疗,对比两组的妊娠结局,治疗有效率和不良反应。结果免疫治疗组治疗成功率为82.56%,明显高于安胎治疗组的20.93%,差异具有统计学意义(P<0.05);安胎治疗组不良反应发生率为2%,免疫治疗组不良反应发生率为4%,差异无统计学意义(P>0.05)。结论淋巴细胞免疫治疗复发性流产的有效率高,不良反应较低,是一种安全有效的治疗方式。

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号